University at Buffalo - The State University of New York
Skip to Content
Official UB news and information for the media

Buffalo Institute for Genomics and Data Analytics signs $1.48M contract with medical device company; to create 40 jobs

Release Date: July 28, 2016

“I’m thrilled to welcome Garwood Medical as the first of many BIG strategic partnerships that will move the institute forward. This collaboration expands our faculty and industry engagement to further critical, life-saving research.”
Brian McIlroy, executive director, BIG
University at Buffalo

BUFFALO, N.Y. – The Buffalo Institute for Genomics and Data Analytics (BIG) – a University at Buffalo program and key component of Gov. Andrew M. Cuomo’s $100 million initiative to transform New York State into a national center for genomic medicine research – today announced a contract with Garwood Medical Devices LLC (GMD) that will create 40 new jobs in five years.

GMD, a medical device company participating in the START-UP NY program, is developing a new class of programmable electrical stimulation devices with integrated sensor and communications technologies to enable unprecedented treatment for chronic wound healing, bone growth and peri-prosthetic (implant) infections, while simultaneously enhancing quality of life by enabling enhanced patient mobility and decreasing the need for clinician intervention.

As part of the agreement, BIG will provide $1.48 million in technology and resource support to GMD, which has committed to the creation of 40 jobs, and a licensed UB intellectual property royalty stream.

“I’m thrilled to welcome Garwood Medical as the first of many BIG strategic partnerships that will move the institute forward,” said BIG Executive Director Brian McIlroy. “This collaboration expands our faculty and industry engagement to further critical, life-saving research.”

According to a 2008 article titled Human Skin Wounds: A major and snowballing threat to public health and the economy” in the publication Wound Repair and Regeneration, 6.5 million Americans have chronic wounds, with expenses exceeding $25 billion per year. Nearly 8 percent of the U.S. population is diabetic, and prone to slow-healing wound infections and ulcers.

Wayne D. Bacon, chairman and CEO of GMD, said, “We are very excited to have established a unique relationship with the University at Buffalo, licensing their valuable patented technologies and collaborating with an interdisciplinary team of six UB professors to bring our novel devices to market. Together, we seek to save the health care system in the U.S. and abroad a large portion of the staggering cost spent on wound healing and implant infections, while simultaneously greatly reducing patient pain and suffering.”

Garwood will hold a press conference and investor reception at their new offices in the UB Gateway Building in downtown Buffalo in early September to introduce the public to their technology platform and strategic initiatives.

Edward Furlani, who holds joint appointments in UB’s departments of Chemical and Biological Engineering and Electrical Engineering, will lead the research and development team, leveraging UB’s comprehensive faculty expertise in device processes, modeling and design, prototype fabrication and characterization, software communications, high performance computing and bioinformatics to aid GMD on their commercialization path.

“This public-private partnership is just one example of the breakthroughs and innovations that can be realized in Western New York, when you combine the universities assets with industry,” said McIlroy.

Media Contact Information